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Abstract 18 
Blooms of the toxic dinoflagellate Alexandrium tamarense (Group 1) seriously impacted the 19 
Tasmanian shellfish industry during 2012 and 2015, necessitating product recalls and intensive 20 
paralytic shellfish toxin (PST) product testing. The performance of four commercial PST test kits, 21 
Abraxis™, Europroxima™, Scotia™ and Neogen™, was compared with the official AOAC LC-FLD 22 
method for contaminated mussels and oysters. Abraxis and Europroxima kits underestimated PST in 23 
35-100% of samples when using standard protocols but quantification improved when concentrated 24 
2 
 
extracts were further diluted (underestimation ≤18%). The Scotia kit (cut off 0.2-0.7 mg STX-diHCl 25 
eq/kg) delivered 0% false negatives, but 27% false positives. Neogen produced 5% false negatives 26 
and 13% false positives when the cut off was altered to 0.5-0.6 mg STX-diHCl eq/kg, the introduction 27 
of a conversion step eliminated false negatives. Based on their sensitivity, ease of use and 28 
performance, the Neogen kit proved the most suitable kit for use with Tasmanian mussels and oysters. 29 
Once formally validated for regulatory purposes, the Neogen kit could provide shellfish growers with 30 
a rapid tool for harvesting decisions at the farm gate. Effective rapid screening preventing compliant 31 
samples undergoing testing using the more expensive and time consuming LC-FLD method will result 32 
in significant savings in analytical costs. 33 
 34 
Keywords: Paralytic Shellfish Toxins, Alexandrium tamarense, immunological test kits, gonyautoxin 35 
1&4. 36 
 37 
1. Introduction  38 
In recent years recurrent blooms (up to 300,000 cells/L) by the Paralytic Shellfish Toxin (PST) 39 
producing dinoflagellate Alexandrium tamarense (Group 1) have seriously impacted the Tasmanian 40 
shellfish industry. An initially undetected bloom event in October 2012 led to product recalls with an 41 
estimated economic loss of ~US$24 million dollars (Campbell et al., 2013). The regulatory action 42 
limit or permissible concentration of PST toxins in shellfish is 0.8 mg STX-diHCl eq/kg shellfish 43 
meat (0.8 mg STX eq/kg from now on). During 2015 closures of oyster and mussel farms which 44 
lasted for up to 4 months, PST levels were instigated and reached up to 32 mg STX eq/kg, resulting in 45 
four documented hospitalizations that occurred after individuals consumed wild mussels (i.e. 46 
recreational harvesting) from an affected area with public health warning signs. The current system 47 
for shellfish testing by the Tasmanian Shellfish Quality Assurance Program (TSQAP) requires 48 
shipping samples to an accredited Sydney laboratory leading to delays (4 to 12 days) for shellfish 49 
growers. The AOAC Official Method AOAC.2005.06 (pre-column oxidation or Pre-COX) using 50 
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liquid chromatography with fluorescence detection (LC-FLD or Lawrence method; Lawrence et al., 51 
2005) is the designated regulatory method for PST in shellfish in Australia. The method is highly 52 
specific and sensitive, providing a complete toxin profile and concentration of each PST analogue. 53 
However, it has been claimed that the method overestimates gonyautoxin 1&4 (GTX1&4) and 54 
neosaxitoxin (NEO), and underestimates gonyautoxin 2&3 (GTX2&3) and sulfocarbamoyl C1&2 55 
compared to AOAC Official method 2011.02 (post-column oxidation or PCOX) (Turner et al., 56 
2014a). Immunological PST test kits, which were first trialled in the early 2000s (Jellett et al., 2002; 57 
Laycock et al., 2000), have the advantage of being sensitive, fast, easy to use and cheaper than HPLC-58 
based analytical methods, and ideally allow farmers to perform tests on site to guide harvesting 59 
decisions. However, due to significant variability in PST toxin profiles of different Alexandrium 60 
species and geographic populations, as well as widely different potency of PST analogues, the 61 
applicability of different commercial test kits for local product testing requires careful consideration. 62 
Most available kits target saxitoxin (STX), but have low cross-reactivity for GTX1&4 and GTX2&3. 63 
The latter are common in Australian shellfish products as well as shellfish in Great Britain (Turner et 64 
al., 2014b).  65 
Enzyme-linked immunosorbent assays (ELISA), such as the Abraxis™ and Europroxima™ kits, are 66 
quantitative tests that allow the user to calculate the concentration of PST toxins (as mg STX eq/kg) 67 
using a STX standard curve. These protocols require laboratory experience to avoid high user errors. 68 
By contrast, lateral flow immunoassays (LFIA) are qualitative tests that deliver positive or negative 69 
results based on a predetermined cut off limit. Scotia Rapid Test™ (formerly Jellett Rapid Test; Jellett 70 
et al., 2002) has a detection limit of ~0.2-0.7 mg STX eq/kg, whereas Neogen™ states that it has a cut 71 
off of 0.8 mg STX eq/kg. LFIA kits are more user friendly and simpler to use than ELISA kits, while 72 
laboratory experience is not essential. Different commercial immunological tests exhibit highly 73 
variable cross-reactivity to different PST analogues (Table 1). These cross-reactivity profiles do not 74 
fully correlate with the toxicity of individual toxins as determined by the mouse bioassay and the 75 
toxicity equivalency factors applied in total toxin determination of the LC-FLD method. Therefore, 76 
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commercial test kits must be shown to be fit for purpose with geographical toxin profiles prior to 77 
implementation within testing regimes. 78 
Table 1. Cross-reactivity (mole %) of four immunological test kits as specified by the manufacturers. 79 
 Quantitative Qualitative 
PST analogue Abraxis Europroxima Neogena Scotiab 
STX 100 100 100 100 
NEO 1.3 1.4 129 26 
GTX2&3 23 5.6 23 100 
GTX1&4 <0.2 <0.1 6 1.8c 
C1&2 nd 0.2 3 nd 
GTX5 23 26.2 23 62 
dcSTX 29 19.2 56 100 
dcNEO 0.6 0.5 28 nd 
dcGTX2&3 1.4 0.2 8 15 
a
 Jawaid et al. (2015)  80 
b
 Formerly Mist Alert and Jellett (Jellett et al., 2002; Laycock et al., 2000) 81 
c
 If an extra step involving hydrolysis conversion of GTX1&4 to NEO is performed, this cross-82 
reactivity can be increased to 26% 83 
nd = not determined 84 
In the present study the performance of four commercially available immunological PST test kits for 85 
shellfish testing were evaluated during a major Alexandrium tamarense bloom event on Tasmania’s 86 
East Coast, Australia, between July and November 2015. 87 
2. Materials and Methods 88 
2.1. Shellfish samples 89 
Sixty nine shellfish samples, including mussel Mytilus galloprovincialis and Pacific oyster 90 
Crassostrea gigas, which originated from 12 farms along the East Coast of Tasmania, Australia were 91 
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used. Samples (homogenates from whole organisms) were stored at -20°C and analysed within 1 92 
month after harvesting. 93 
2.2. Liquid chromatography analysis 94 
Advanced Analytical Australia (AAA), the certified laboratory that TSQAP uses for phycotoxin 95 
analysis, determined PST toxin concentration using the AOAC.2005.06, LC-FLD or Lawrence 96 
method. Screen and confirmation (when >0.4 mg STX eq/kg were found) analyses of the method were 97 
performed.  98 
PST toxins were extracted from 5 g of shellfish homogenate using 3 mL of 1% acetic acid. The 99 
mixture was placed in a boiling water bath for 20 min, mixed, allowed to cool and centrifuged at 3600 100 
×g for 10 min. The supernatant was recovered and the pellet resuspended in 3 mL 1% acetic acid, 101 
mixed and centrifuged again. Both supernatants were mixed and made up to 10 mL with water. A 102 
sample clean-up was performed using a SPE C18 cartridge and screen testing was performed after 103 
periodate oxidation of samples. Standards, samples and PST positive certified reference matrices were 104 
oxidised with the inclusion of a matrix modifier. The matrix chosen for the matrix modifier reflected 105 
the predominant shellfish in the run. Oxidation using the matrix modifier circumvents the need to 106 
apply recovery factors for differing shellfish matrices. A further confirmation analysis was performed 107 
after peroxide oxidation of C18 cleaned extracts. All results were converted to mg STX-diHCl eq/kg 108 
using EFSA’s toxicity equivalency factors (EFSA, 2009) (mentioned as mg STX eq/kg). Subsamples 109 
analysed by AAA were returned to IMAS for use in the PST screening with the rapid test kits. 110 
2.3. Test kits 111 
2.3.1. Quantitative Tests 112 
Abraxis™  113 
Abraxis test kits (52255B, lot number 15B5951) were stored at 4°C until analysis. PST toxin 114 
quantification was performed according to the manufacturer’s protocol.  115 
Extract preparation 116 
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A subsample of 10 g of shellfish homogenate was mixed with 10 mL of 0.1 M HCl (modified version 117 
of the AOAC.959.08 method, extraction protocol as per the mouse bioassay) and placed in a boiling 118 
water bath for 5 min, allowed to cool down and centrifuged at 3500 ×g for 10 min. Supernatants were 119 
recovered and pH adjusted to 3.0, and diluted in 1x sample diluent (1:1000). Initially, all 69 samples 120 
were considered as blind samples and analysed as per the standard test protocol (i.e. 1:1000 dilution). 121 
For a second analysis, 15 of these samples were further diluted (i.e. 1:10 or 1:100) based on the 122 
known toxin concentration (LC-FLD by AAA) in order to bring them within the working range of the 123 
calibration curve. 124 
 The Abraxis kit can operate with an alternative extraction method using 80% methanol (MeOH). For 125 
this purpose the 15 samples mentioned above (i.e. with extra dilution performed) were tested. 126 
Shellfish homogenate (1 g) was mixed with 6 mL of MeOH for 1 min using a Vortex mixer, 127 
centrifuged at 3000 ×g for 10 min and the supernatant transferred into a clean tube. MeOH (2 mL) 128 
was added to the pellet, mixed and centrifuged. Both supernatants were combined and made up to 10 129 
mL with MeOH. Similar to the HCl extracts, the MeOH extracts were analysed using the standard test 130 
protocol dilution (1:100) and also with an extra dilution (i.e. 1:10 or 1:100) as required.  131 
Test protocol 132 
A volume of 50 µL of STX standards (provided at 0, 0.02, 0.05, 0.10, 0.20 and 0.40 ng mL-1) and 133 
samples (in HCl or MeOH) was transferred into the 96-well coated plate in duplicate, followed by 50 134 
µL of enzyme conjugate and 50 µL of antibody. The microplate was mixed and incubated for 30 min 135 
at room temperature. Solutions were decanted and wells rinsed four times with 1x washing buffer 136 
solution. Substrate solution was added to all wells (100 µL), mixed and incubated for 30 min in the 137 
dark. Stop solution was added to the wells (100 µL) and mixed, with the absorbance read immediately 138 
at 450 nm using a microplate reader (FLUOstar OPTIMA, BMG Labtech 413-3350). For data 139 
analysis, %B/B0 values (i.e. average absorbance of STX standards divided by average absorbance of 140 
blank standard) were obtained and toxin quantification in samples determined by interpolating 141 
response values in the standard curve. 142 
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Europroxima™ 143 
Europroxima test kits (5191SAXI, lot number QN5327) were stored at 4°C until analysis. 144 
Manufacturer’s protocol was followed to perform the test. Similar to the Abraxis test kits, all samples 145 
were considered as blind samples, with an extra set of 15 samples further diluted (i.e. 1:10, 1:100 or 146 
1:500) based on the known toxin concentration.  147 
Extract preparation 148 
In brief, 1 g of shellfish homogenate was mixed with 5 mL of 0.2 M sodium acetate buffer (freshly 149 
prepared), centrifuged at 3000 ×g for 10 min and the supernatant recovered for experiments. The 150 
extract was diluted in dilution buffer (1:50).  151 
Test protocol 152 
STX standards (0.0125, 0.025, 0.05, 0.1, 0.2 and 0.3 ng mL-1) and samples (50 µL) were transferred 153 
into the 96-well plate in duplicate, followed by 25 µL of conjugate and 25 µL of antibody. The plate 154 
was shaken for 1 min and incubated for 30 min at room temperature. The solutions were discarded 155 
and all wells rinsed three times with rinsing buffer. Substrate was added to all wells (100 µL), the 156 
plate was shaken and incubated for 15 min at room temperature in the dark. Stop solution was added 157 
(100 µL) and absorbance was read immediately at 450 nm. % maximal OD (optical density) was 158 
calculated for all standards and samples using the absorbance readings from the standards with no 159 
STX (standard zero, provided by supplier). The concentration of PST in samples was calculated using 160 
the calibration curve. 161 
2.3.2. Qualitative Tests 162 
Scotia™ 163 
Scotia test kits (PSP Rapid Test, lot number 40000) were stored at 5°C until analysis. These kits use 164 
the modified AOAC.959.08 extraction method boiling the shellfish sample in 0.1 M HCl (or mini-165 
AOAC, Jellett et al., 2002), and thus the same extracts prepared for the Abraxis tests were used for the 166 
Scotia kits. Manufacturer’s protocol was followed for the test. A volume of 400 µL of PSP Scotia 167 
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rapid buffer was mixed with 100 µL of the shellfish extract, 100 µL of this mix was placed into the 168 
test kit sample slot and allowed to develop for 35 min. The test kits were scanned using the Scotia 169 
Skannex system, which scans the strip and analyses the bands to give a positive or negative result 170 
with a numeric value based on the intensity comparison of both the C (control) and T (test) bands. 171 
Values ≥0.5 indicate negative samples, or positive if <0.5 (Turner et al., 2015). 172 
Neogen™ 173 
Neogen test kits (NEO9562, lot number 9562-11) were stored at room temperature until analysis. The 174 
certificate analysis report accompanying the kits showed that STX-diHCl standards at two 175 
concentrations equivalent to 0.16 mg/kg and 0.80 mg/kg returned negative and positive results, 176 
respectively, with no further information in performance within that concentration range. Neogen’s 177 
standard protocol uses 1 g (±0.05 g) of shellfish homogenate mixed with 30 mL (±0.5 mL) of distilled 178 
water in a plastic extraction bag with an inner mesh filter (280 µM pore size, provided with kits) to 179 
perform the toxin extraction manually using the metal roller. The filtered liquid (extract) is recovered 180 
and 100 µL of this is transferred into a container with buffer saline solution (as provided) and mixed 181 
for 30 s. A volume of 100 µL of this mix is then transferred into a microwell and a LFIA test strip 182 
inserted and allowed to develop for exactly 5 min, after which it is placed into the AccuScan Pro 183 
Reader to obtain the positive or negative result based on the intensity of the test band that appears in 184 
the strip (see Jawaid et al., 2015).  185 
Standard curves with the Neogen test kit 186 
The analysis of standard curves of different PST analogues was performed to test the cut off levels for 187 
each analogue using the same dilutions as the Neogen standard protocol. Standards of STX, NEO, 188 
GTX2&3, GTX1&4 and C1&2 were purchased from the National Research Council Canada (NRC). 189 
Saxitoxin standard was tested at concentrations equivalent to 0.1, 0.2, 0.3, 0.4, 0.5, 0.6, 0.7 and 0.8 190 
mg/kg following the standard Neogen protocol (i.e. 1:31 sample dilution). STX, NEO, GTX2&3, 191 
GTX1&4 and C1&2 standards were tested again but now using the adjusted dilution at concentrations 192 
of 0.2, 0.3, 0.4, 0.5, 0.6, 0.7, 0.8 and 1.2 mg STX eq/kg. Additionally, two mixtures of these standards 193 
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recreating what has been observed in natural contaminated samples were tested. Mix A: 1, 60, 30 and 194 
9 % of STX, GTX1&4, GTX2&3 and C1&2, respectively, and mix B: 0.5, 90, 4.5 and 5.0 %, 195 
respectively. A concentration range of 0.2, 0.4, 0.6, 0.8 and 1.2 mg STX eq/kg were tested. For toxins 196 
that were combined, only the epimer with greatest toxicity was used for calculative purposes, using 197 
the EFSA toxicity equivalency factors (EFSA, 2009). In addition, because of the low reactivity (6%) 198 
of Neogen test towards GTX1&4, two extra batches of GTX1&4 were treated with L-cysteine (Sigma 199 
W326305), to explore the possibility of PST analogue conversion (Asakawa et al., 1987) and thus 200 
increase the reactivity of the Neogen kit. The second batch of GTX1&4 (at 0.2-1.2 mg STX eq/kg) 201 
was incubated with cysteine (2 M) in a water bath at 70°C for 30 min, and the third batch was treated 202 
under the same conditions but for 60 min. 203 
Test of shellfish samples 204 
The first dilution step was modified since we observed that STX standard at 0.4 mg/kg returned a 205 
positive result when mixing 1 g of shellfish sample (or equivalent standard) with 30 mL of type 1 206 
water, the new dilution was using 45.5 mL of type 1, 18.2 MΩ∙cm, water. Sixty nine shellfish samples 207 
were tested using 1 g (±0.05 g) of homogenate and extracted with 45.5 mL of type 1 water; the rest of 208 
the protocol was as mentioned previously. The Neogen standard protocol (i.e. dilution of 1:31 during 209 
extraction) was used only for 11 shellfish samples that included false negatives; a cysteine treatment 210 
was also applied to these 11 samples but that were extracted at a dilution of 1:46.5 (extract incubated 211 
with 2 M cysteine at 70°C for 30 min). Once all the tests were completed and positive/negative results 212 
registered, the data recorded by the Neogen AccuScan Pro Reader was exported to Excel (Microsoft 213 
Office™), which includes peak and area values for both the control and test bands, plus the positive or 214 
negative result corresponding to the test band. 215 
3. Results 216 
Using the LC-FLD analytical method, 23 of the 69 samples had PST levels same as or above the 217 
action limit of 0.8 mg STX eq/kg (non-compliant), 33 samples had levels ranging between 0.10 and 218 
0.77 mg STX eq/kg, and 13 samples levels of <0.10 mg STX eq/kg (compliant) (Table S1, 219 
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Supplementary material). Most contaminated samples contained high proportions of the PST 220 
analogues GTX1&4 (25-88%) and GTX2&3 (8-70%), followed by C1&2 (4-21%) and STX (0-3%) 221 
(Fig. 1). Due to the varying nature of the shellfish matrices, toxin profiles and concentrations, multiple 222 
SPE steps, and pH variances in the oxidation steps, the standard error is fairly high at lower 223 
concentrations. 224 
 225 
Fig. 1. Proportion of PST analogues in contaminated shellfish during an Alexandrium tamarense 226 
(group 1) bloom in Tasmania, Australia, as per Table S1 from Supplementary material. Only samples 227 
with ≥0.80 mg STX eq/kg of LC-FLD confirmation analysis are shown.  228 
 229 
3.1. Quantitative ELISA kits 230 
3.1.1. Abraxis 231 
The Abraxis kit showed poor performance on the 69 shellfish samples when the standard protocol was 232 
followed; 8 of the 23 non-compliant samples (34.8%) were underestimated, delivering values below 233 
the regulatory action limit (i.e. between 0.24 and 0.77 mg STX eq/kg) in samples containing 0.80-3.29 234 
mg STX eq/kg (as per LC-FLD). Correlation between Abraxis and LC-FLD was poor (r2=0.33 for 235 
linear adjustment) (Fig. 2A). Performance of the Abraxis kit increased when shellfish extracts were 236 
diluted (up to 1:100000) based on the LC-FLD toxin concentrations. Such tests were performed on 15 237 
samples, of which 11 had PST levels >0.8 mg STX eq/kg. Shellfish samples extracted with 80% 238 
MeOH showed very similar results as the HCl extracts. Abraxis quantification of HCl and MeOH 239 
extracts with extra dilutions improved considerably showing higher correlations with the LC-FLD 240 
method, increasing from r2=0.38-0.39 to r2=0.82-0.91 (Fig. 2B). Despite the improvement in the 241 
performance with the extra dilution step (performed in 15 samples, of which 11 were non-compliant), 242 
2 samples (18%) with 0.92-0.97 mg STX eq/kg (LC-FLD) were underestimated by Abraxis, 243 
generating values below the action limit (Table 2). 244 
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 245 
Fig. 2. Quantification of PST in Tasmanian shellfish samples using the Abraxis™ ELISA kit as 246 
compared with the AOAC.2005.06 (LC-FLD) official method. Values are average from duplicate 247 
samples (see Table 2). A) All 69 samples with equations from linear and logarithmic regressions. 248 
Linear regression is the desired adjustment; however the logarithmic adjustment showed a better 249 
correlation, showing the limitation of the Abraxis test for an accurate quantification of concentrated 250 
PST extracts. B) Extra analysis of 15 samples using two extraction techniques (HCl and MeOH) with 251 
an extra sample dilution step. 252 
 253 
3.1.2. Europroxima 254 
The Europroxima kit showed poor performance on the 69 shellfish extracts. All 23 samples with ≥0.8 255 
mg STX eq/kg were underestimated, delivering values of 0.10-0.19 mg STX eq/kg when 256 
manufacturer’s protocol was followed (using sample dilution of 1:50 prior). Correlation between 257 
Europroxima and LC-FLD quantification was poor (r2=0.13, linear adjustment) (Fig. 3A). 258 
Quantification was improved by performing an extra dilution to the samples based on their known 259 
PST concentrations. Due to the high PST levels in some samples, extra dilutions of up to 1:500 were 260 
required (final dilution of 1:150000). The correlation between Europroxima and LC-FLD improved 261 
from r2=0.0004 to 0.91 in the 15 samples that were diluted, which included 11 non-compliant (Fig. 262 
3B). However, one sample with 0.92 STX eq/kg (LC-FLD) was still underestimated by Europroxima, 263 
as having 0.44 mg STX eq/kg (Table 2).  264 
 265 
Fig. 3. Quantification of PST shellfish samples using the Europroxima™ ELISA kit compared to the 266 
AOAC.2005.06 (LC-FLD) official method. Values correspond to average of duplicate samples, and 267 
bars represent their standard deviations (see Table 2). A) 69 samples with equations from linear and 268 
logarithmic regressions are shown for each protocol. Similarly to Abraxis, Europroxima showed 269 
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limitations in quantification of concentrated samples. B) Extra analysis in 15 samples following the 270 
standard protocol and an extra sample dilution. 271 
 272 
3.2. Qualitative LFIA kits 273 
3.2.1. Scotia 274 
The Scotia kit showed good performance on high PST shellfish. However, considering that the 275 
sensitivity is 0.2-0.7 mg STX eq/kg (Scotia Rapid Testing, pers. comm.), the test kits delivered 16 276 
false positives (27%). Among these, 9 contained 0.10-0.19 mg STX eq/kg and the other 7 were 277 
reported as <0.10 mg STX eq/kg by the LC-FLD method (Fig. 4). No false negatives were detected 278 
using the Scotia test but only 9 of the 18 shellfish extracts with ≤0.2 mg STX eq/kg were negative 279 
(Table 2). The PST concentration in shellfish extracts and numerical values recorded by the Scotia 280 
scanner were not well correlated (r2=0.26-0.45) (Fig. 4). 281 
 282 
Fig. 4. PST toxin tests using the Scotia kit in 69 shellfish samples (A) with PST concentration as per 283 
the LC-FLD method (mg STX eq/kg) on the x-axis, showing those with <0.8 mg STX eq/kg in (B), 284 
where the sensitivity of the Scotia test is shaded (0.2-0.7 mg STX eq/kg) and positive results were 285 
expected. The y-axis indicates the numerical value generated by the Scotia Skannex system based on 286 
the intensity comparison of the control and test bands of the test. Values ≥0.5 indicate negative 287 
samples (●), or positive if <0.5 ( ). False positives ( ) are those samples with ≤0.20 mg STX eq/kg 288 
(LC-FLD analysis) but generated a positive result. See Table S2 (Supplementary material) for 289 
complete list of numerical values. 290 
 291 
 292 
 293 
 294 
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3.2.2. Neogen 295 
Performance of the Neogen kit using PST toxin standards is shown in supplementary material (Figs. 296 
S1 and S2). 297 
Performance on contaminated shellfish samples 298 
Control bands showed an average peak and area of 8192 (±555) and 11755 (±696), respectively (data 299 
not shown). Both values for peak and area for the test bands of the 69 samples were highly correlated 300 
(Table S2 and Fig. S3, Supplementary material). Although peak and area values generally depended 301 
on toxin concentration, their quantitative values may not always be indicative due to varying cross-302 
reactivity for different PST analogues.  303 
Neogen performed well on most of the 69 shellfish samples. Considering that the dilution in the 304 
extraction step was modified from 1:31 (cut off observed to be 0.4 mg STX eq/kg) to 1:46.5 to set the 305 
cut off to 0.5-0.6 mg STX eq/kg, Neogen delivered false positives in only 4 samples (13%), three of 306 
which had 0.10 to <0.35 mg STX eq/kg and the other contained 0.03 mg STX eq/kg (as per the LC-307 
FLD method). Two false negatives (5%) were observed in samples with 0.82 and 0.92 mg STX eq/kg 308 
(Table 2). These samples were reanalysed following the Neogen standard protocol (dilution 1:31): the 309 
sample with 0.92 mg STX eq/kg turned positive, but the sample with 0.82 mg STX eq/kg was still 310 
negative (false negative). To overcome this, cysteine treatment (2 M at 70°C for 30 min) was applied 311 
to the two false negative samples (1:46.5 dilution), together with 9 other samples of varying toxin 312 
concentrations. Cysteine treatment effectively eliminated the false negatives, although one other false 313 
positive was generated (at 0.20 mg STX eq/kg) (Table 3). 314 
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Table 2. Summary of the performance of the four PST kits on 69 shellfish samples. The confirmation results determined by LC-FLD are included. PST 315 
quantification on 15 samples was further investigated with the Abraxis kit by using the two recommended extraction methods (HCl and MeOH), following 316 
the standard protocol and by performing an extra dilution step. This was also done for Europroxima. Results shaded in gray indicate false positives (Neogen 317 
and Scotia) and in black false negatives (Neogen) based on the sensitivity of each kit (0.2-0.7 mg STX eq/kg for the Scotia test, and altered to 0.5-0.6 mg 318 
STX eq/kg for Neogen). NT = not tested. 319 
Sample LC-FLD (mg 
STX eq/kg) 
Neogen Scotia Abraxis HCl Abraxis MeOH Europroxima 
Normal Extra Normal Extra Normal Extra 
Mean SD Mean SD Mean SD Mean SD Mean SD Mean SD 
1 9.20 + + 1.11 0.02 NT  NT  NT 
 
0.15 0.12 NT  
2 5.85 + + 1.04 0.01 NT  NT  NT 
 
0.12 0.05 NT  
3 4.83 + + 0.96 0.01 NT  NT  NT 
 
0.14 0.16 NT  
4 5.65 + + 1.16 0.02 NT  NT  NT 
 
0.13 0.08 NT  
5 3.20 + + 1.01 0.06 NT  NT  NT 
 
0.13 0.02 NT  
6 3.02 + + 0.87 0.00 NT  NT  NT 
 
0.12 0.01 NT  
7 3.29 + + 0.93 0.03 NT  NT  NT 
 
0.13 0.04 NT  
8 1.10 + + 0.68 0.00 NT  NT  NT 
 
0.10 0.00 NT  
9 0.96 + + 0.77 0.05 NT  NT  NT 
 
0.13 0.01 NT  
10 0.98 + + 0.44 0.02 NT  NT  NT 
 
0.12 0.04 NT  
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11 1.10 + + 0.66 0.02 NT  NT  NT 
 
0.15 0.06 NT  
12 0.82 - + 0.32 0.01 NT  NT  NT 
 
0.11 0.01 NT  
13 31.75 + + 1.05 0.01 15.51 0.24 0.48 0.02 18.94 3.17 0.15 0.00 31.70 4.81 
14 24.44 + + 1.05 0.01 24.78 0.02 0.41 0.02 20.04 1.58 0.15 0.03 41.22 11.16 
15 13.38 + + 1.12 0.01 5.51 0.15 0.38 0.01 3.48 0.04 0.16 0.04 14.49 0.17 
16 7.21 + + 1.01 0.01 4.32 0.02 0.48 0.00 3.30 0.02 0.16 0.06 8.95 0.75 
17 5.23 + + 0.89 0.00 2.59 0.02 0.37 0.00 2.51 0.00 0.16 0.10 5.07 0.47 
18 2.26 + + 0.85 0.02 2.47 0.04 0.39 0.02 1.90 0.03 0.14 0.03 4.78 0.07 
19 0.80 + + 0.74 0.01 1.09 0.01 0.38 0.01 1.79 0.34 0.18 0.10 1.29 0.41 
20 0.97 + + 0.73 0.02 0.75 0.00 0.31 0.00 0.70 0.01 0.16 0.06 1.93 0.08 
21 1.43 + + 0.81 0.03 1.34 0.03 0.38 0.01 1.23 0.01 0.19 0.05 2.63 0.07 
22 2.24 + + 0.92 0.04 1.94 0.01 0.42 0.01 2.50 0.44 0.15 0.03 3.61 0.37 
23 0.92 - + 0.24 0.00 0.34 0.00 0.31 0.03 0.27 0.00 0.12 0.02 0.44 0.05 
24 0.75 + + 0.69 0.01 0.52 0.00 0.30 0.00 0.61 0.04 0.15 0.08 0.57 0.05 
25 0.77 + + 0.76 0.02 1.08 0.01 0.28 0.00 1.13 0.02 0.15 0.06 1.07 0.35 
26 0.42 - + 0.69 0.01 0.51 0.02 0.28 0.01 0.49 0.01 0.16 0.06 0.65 0.01 
27 0.33 - + 0.43 0.01 0.29 0.00 0.22 0.00 0.23 0.00 0.10 0.03 0.41 0.01 
28 0.70 + + 0.65 0.02 NT  NT  NT 
 
0.15 0.03 NT 
 
29 0.49 + + 0.60 0.01 NT  NT  NT 
 
0.12 0.02 NT 
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30 0.77 + + 0.68 0.01 NT  NT  NT 
 
0.12 0.04 NT  
31 0.48 - + 0.44 0.01 NT  NT  NT 
 
0.11 0.01 NT 
 
32 0.41 - + 0.30 0.00 NT  NT  NT 
 
0.10 0.00 NT 
 
33 0.22 + + 0.46 0.00 NT  NT  NT 
 
0.12 0.01 NT 
 
34 0.29 - + 0.40 0.01 NT  NT  NT 
 
0.12 0.05 NT 
 
35 0.34 - + 0.40 0.01 NT  NT  NT 
 
0.13 0.07 NT 
 
36 0.31 - + 0.31 0.00 NT  NT  NT 
 
0.12 0.06 NT 
 
37 0.21 - + 0.47 0.01 NT  NT  NT 
 
0.12 0.04 NT 
 
38 0.20 - + 0.36 0.01 NT  NT  NT 
 
0.11 0.01 NT 
 
39 0.34 - + 0.34 0.00 NT  NT  NT 
 
0.12 0.02 NT 
 
40 0.36 - + 0.34 0.00 NT  NT  NT 
 
0.12 0.05 NT 
 
41 0.23 - + 0.22 0.00 NT  NT  NT 
 
0.10 0.01 NT 
 
42 0.15 - + 0.43 0.00 NT  NT  NT 
 
0.09 0.03 NT 
 
43 0.10 + + 0.49 0.01 NT  NT  NT 
 
0.11 0.02 NT 
 
44 0.11 - + 0.39 0.01 NT  NT  NT 
 
0.11 0.01 NT 
 
45 0.04 - + 0.33 0.01 NT  NT  NT 
 
0.12 0.00 NT 
 
46 0.08 - + 0.23 0.00 NT  NT  NT 
 
0.10 0.02 NT 
 
47 0.03 + + 0.38 0.00 NT  NT  NT 
 
0.11 0.04 NT 
 
48 <0.35 + + 0.35 0.01 NT 
 
NT 
 
NT 
 
0.11 0.01 NT 
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49 <0.20 - + 0.38 0.00 NT 
 
NT 
 
NT 
 
0.09 0.02 NT 
 
50 <0.20 - + 0.33 0.00 NT 
 
NT 
 
NT 
 
0.09 0.01 NT 
 
51 <0.10 - + 0.13 0.00 NT 
 
NT 
 
NT 
 
0.07 0.01 NT 
 
52 <0.20 - + 0.28 0.00 NT 
 
NT 
 
NT 
 
0.11 0.02 NT 
 
53 <0.03 - - 0.05 0.00 NT 
 
NT 
 
NT 
 
0.04 0.00 NT 
 
54 <0.03 - - 0.07 0.00 NT 
 
NT 
 
NT 
 
0.05 0.00 NT 
 
55 <0.15 - - 0.20 0.01 NT 
 
NT 
 
NT 
 
0.10 0.00 NT 
 
56 <0.21 - - 0.21 0.00 NT 
 
NT 
 
NT 
 
0.09 0.01 NT 
 
57 <0.20 - + 0.16 0.00 NT 
 
NT 
 
NT 
 
0.07 0.01 NT 
 
58 <0.15 - - 0.05 0.00 NT 
 
NT 
 
NT 
 
0.08 0.01 NT 
 
59 <0.03 - - 0.06 0.00 NT 
 
NT 
 
NT 
 
0.09 0.00 NT 
 
60 <0.20 - + 0.14 0.00 NT 
 
NT 
 
NT 
 
0.10 0.03 NT 
 
61 <0.10 - - 0.04 0.00 NT 
 
NT 
 
NT 
 
0.07 0.01 NT 
 
62 <0.20 - + 0.28 0.00 NT 
 
NT 
 
NT 
 
0.11 0.03 NT 
 
63 <0.05 - - 0.10 0.00 NT 
 
NT 
 
NT 
 
0.10 0.01 NT 
 
64 <0.07 - - 0.00 0.00 NT 
 
NT 
 
NT 
 
0.16 0.04 NT 
 
65 <0.05 - + 0.04 0.00 NT 
 
NT 
 
NT 
 
0.10 0.01 NT 
 
66 <0.33 - + 0.50 0.01 NT 
 
NT 
 
NT 
 
0.12 0.02 NT 
 
67 <0.08 - + 0.10 0.00 NT 
 
NT 
 
NT 
 
0.09 0.01 NT 
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68 <0.26 - + 0.04 0.00 NT 
 
NT 
 
NT 
 
0.09 0.01 NT 
 
69 <0.08 - + 0.06 0.00 NT 
 
NT 
 
NT 
 
0.08 0.01 NT 
 
320 
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Table 3. Comparison of the Neogen standard protocol (dilution 1:31) against two modifications 321 
(dilution 1:46.5 with or without cysteine 2 M, 70°C, 30 min). The four main PST analogues in the 322 
samples are indicated together with the total concentration (confirmation result). Shaded results 323 
indicate false negatives (eliminated when treated with cysteine). Sample numbers are the same as in 324 
Table 2. All these samples tested positive with the Scotia kit.  325 
Sample 
No. 
Total PST 
mg STX eq/kg 
STX GTX1&4 GTX2&3 C1&2 1:31 1:46.5 1:46.5 + 
cysteine 
12 0.82 * 62% 31% 7% - - + 
23 0.92 * 61% 24% 7% + - + 
30 0.77 * * 64% 18% + + + 
31 0.48 * * 80% 13% - - + 
32 0.41 * 28% 46% 15% - - - 
36 0.31 * 47% 46% 7% - - - 
38 0.20 * * 80% 20% - - + 
44 0.11 * 41% * 28% - - - 
50 <0.20 NA NA NA NA - - - 
67 <0.08 NA NA NA NA - - - 
69 <0.08 NA NA NA NA - - - 
* Reported as <0.05 mg STX eq/kg 326 
NA = Not available 327 
 328 
4. Discussion 329 
Dinoflagellate blooms of Alexandrium tamarense (Group 1) in 2012 and 2015 generated closure of 330 
Tasmanian shellfish farms for up to 4 months, causing major economic losses. Mussels and oysters 331 
contained gonyautoxins as the major PST analogues. In 2012 GTX2&3 was the major analogue (51-332 
100%), followed by STX (14-18%), C1&2 (10-24%) and dcGTX2&3 (5-16%). In contrast, in 2015 333 
GTX1&4 was the major analogue (25-88%), followed by GTX2&3 (8-70%), C1&2 (4-21%) and STX 334 
(0-3%). Due to the low cross-reactivity of commercially available kits for GTX1&4, it was necessary 335 
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to determine which kit would be the most suitable for shellfish growers to potentially incorporate in 336 
their monitoring program. To date few studies have critically compared PST immunological test kit 337 
results against AOAC official methods. Most studies used Scotia (formerly Jellett) and Abraxis (Costa 338 
et al., 2009; DeGrasse et al., 2014a; Turner et al., 2015; Wong et al., 2010), whereas others used 339 
ELISA kits with low or no reactivity to GTX1&4 (Burrell et al., 2016; Sato et al., 2014). The results 340 
of the present study are summarised in Table 4, which compares the main characteristics of the four 341 
immunological PST test kits, ease of use and their performance on Tasmanian mussels and oysters. 342 
To date, PST determination in shellfish samples using AOAC official methods is still subject to 343 
considerable variability (Burrell et al., 2016; Costa et al., 2009; Turner et al., 2014a). A recent study 344 
did not conclusively select a method of choice but rather concluded that the method to choose should 345 
be based on practicality, including access and cost of equipment, and skills of the analyst (Burrell et 346 
al., 2016). A continuous input in methodological improvements and innovations is needed to 347 
overcome current method limitations, efficiency and sample turnaround time (Boundy et al., 2015; 348 
Campbell et al., 2011; Yakes et al., 2012), as well as their application to other matrices, such as 349 
human urine and blood serum (DeGrasse et al., 2014b). 350 
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Table 4. Summary of the characteristics and performance of four immunological commercially available test kits on the detection of PST toxins on 351 
Tasmanian mussels and oysters, which contained mostly GTX1&4. 352 
 Neogen™ Scotia™ Abraxis™ Europroxima™ 
Characteristics     
Cut off or 
working range (mg STX eq/kg) 
0.5-0.6 0.2-0.7  
0.04-0.8a 
 
0.0038-0.09a 
Cross-reactivity for GTX1&4 
(mole %) 
6 1.8 <0.2 <0.1 
Conversion step for GTX1&4 Yes (introduced here) Yes No No 
Improved cross-reactivity for 
GTX1&4 (mole %) 
129 26 - - 
Cost per testb (~US$) 22 22 13c to 84d  12c to 96d 
Extraction Distilled or type 1water, 
manually with roller 
0.1 M HCl,  
boil & centrifuge 
0.1 M HCl,  
boil & centrifuge 
0.2 M sodium acetate buffer, 
mix & centrifuge 
Dilution for extraction 1:31 (standard) 
1:46.5 (present study) 
1:2 1:2 1:6 
Time for analysise 20-35 min 35-95 min Up to 3 hrs Up to 3 hrs 
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Result Positive or negative, 
immediate with reader 
Positive or negative, 
immediate with scanner 
mg STX eq/kg, prior data 
analysis required 
mg STX eq/kg, prior data 
analysis required 
Performance in Tasmanian 
shellfish (n=69) 
    
% False positives  13 27 25f 25f 
% False negatives 5 0g 0 18h 9h 
a
 Working range of shellfish samples calculated from lowest and highest STX standard concentrations provided with kits for calibration curve. 353 
b
 Price does not include taxes and reader, scanner or software for data analysis 354 
c
 Considering that the whole 96-well plate is used, 41 or 40 samples can be tested in a single plate with Abraxis or Europroxima, respectively.  355 
d Considering only one sample is run at a time (unused wells can be stored and used within the expiry date. Used wells must not be re-used) 356 
e
 It does not include preparation of shellfish homogenate 357 
f
 Reported as non-compliant when they in fact contained <0.80 mg STX eq/kg (as per LC-FLD), calculated from the 15 samples with extra dilutions to fit in 358 
the working range of the calibration curve. This corresponds to only one sample (of four) that was reported as 0.77 mg STX eq/kg with the LC-FLD method. 359 
g
 False negatives eliminated with the cysteine conversion step introduced in the present study 360 
h
 Reported as compliant when they in fact contained >0.80 mg STX eq/kg (as per LC-FLD), calculated from the 15 samples with extra dilutions to fit in the 361 
working range of the calibration curve.  362 
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4.1. Ease of use 363 
The advantage of the Abraxis and Europroxima kits is that they deliver a quantitative PST result. A 364 
disadvantage is that both kits require laboratory skills. Abraxis requires extracting the toxin by boiling 365 
the shellfish sample in HCl, but this can be avoided by using MeOH and not boiling. The extraction 366 
step with Europroxima requires preparing the extraction buffer (0.2 M sodium acetate buffer), while 367 
the remaining extraction steps are easy to follow. Both the Abraxis and Europroxima call for pipetting 368 
small volumes (10-100 µL and 25-100 µL, respectively) for dilution and perform the assays using 96-369 
well microplates. Stock solutions (i.e. dilution buffer, wash solution, conjugate or antibody) need to 370 
be diluted, and different incubation periods are required. Total test times amount to 60 and 45 min for 371 
Abraxis and Europroxima, respectively, but including sample extraction and solutions preparation, the 372 
protocol can take up to 3 hrs depending on the number of samples to be tested. Data analysis requires 373 
a calibration curve to be constructed but no specialised software is required. An adaptation of the 96-374 
well plate Abraxis kit into a compact and easy-to-use shipboard version was successfully used by 375 
fishermen during a pilot study in Georges Bank, USA, with good correlations between Abraxis, 376 
mouse bioassay and LC-FLD (DeGrasse et al., 2014a). It is noted that the surf clams tested contained 377 
mostly STX, for which the Abraxis kit is well suited. However, the Abraxis and the Europroxima test 378 
kits had limited applicability to Tasmanian shellfish containing mostly GTX1&4. 379 
The qualitative Scotia and Neogen kits comprise easier steps and laboratory experience is not 380 
essential. Scotia, similar to Abraxis, recommends extracting the toxin by boiling shellfish in HCl, but 381 
it also has an alternate rapid method using a mix of 2.5 parts of 70% isopropyl with 1 part of 5% 382 
acetic acid but this protocol was not performed in the present study. The remainder of the Scotia 383 
protocol involves mixing the shellfish extract with Scotia buffer and transfer an aliquot of this mix 384 
into the test strip followed by 35-60 min incubation period. The strip then can be scanned using the 385 
Scotia Skannex system which delivers an immediate positive or negative result. However, if GTX1&4 386 
is suspected to be the dominant PST analogue, an extra step is recommended which increases the 387 
duration of the test by an extra 60 min. The Neogen kit offers the greatest ease of use since the 388 
extraction step is achieved using distilled water (or type 1 water, as in this study), and no boiling is 389 
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required. Extraction is performed using a plastic filter bag which is homogenised mechanically with a 390 
roller (both provided). An aliquot of this mix is directly poured into a bottle containing Neogen 391 
buffer, which is mixed manually and a subsample used to perform the test. The Neogen strip is 392 
incubated only for 5 min and immediately analysed by the Accuscan Pro reader, which delivers a 393 
positive or negative result. 394 
A drawback of Abraxis and Europroxima is that a microplate reader with absorbance detection is 395 
necessary. Similarly, a scanner and computer are recommended for Scotia to remove subjectivity of 396 
visual interpretation of the bands (Turner et al., 2015). Neogen has also developed their own 397 
dedicated reader (Accuscan Pro reader). Both readers have to be purchased from the companies or 398 
brand suppliers since they use a specific software or have been calibrated in-house. The advantage of 399 
these readers is that they deliver an immediate result. Both Scotia and Neogen kits can be stored at 400 
room temperature (Scotia: 4-25°C, Neogen: 18-30°C), whereas the Europroxima and Abraxis kits 401 
need to be stored at 2-8°C and 4-8°C, respectively. 402 
4.2. Sensitivity and Performance  403 
Both Abraxis and Europroxima tended to underestimate the toxin concentrations in shellfish extracts 404 
when manufacturers’ recommended protocols were followed. Abraxis underestimated in all 23 405 
samples with ≥0.80 mg STX eq/kg, with 15 of these samples (65%) estimating at 0.8-1.2 mg STX 406 
eq/kg (e.g. LC-FLD: 1.43, 9.20, 31.75 mg STX eq/kg = Abraxis: 0.81, 1.11, 1.05 mg STX eq/kg, 407 
respectively). Critically, 8 samples (34.8%) were reported below the recommended regulatory action 408 
limit, within a concentration range of 0.80-3.29 mg STX eq/kg (LC-FLD), which showed 0.24-0.77 409 
mg STX eq/kg with the Abraxis test. All samples extracted with MeOH were underestimated below 410 
the action limit. Europroxima underestimated 100% of samples, including those with up to 31.75 mg 411 
STX eq/kg. In some cases, Abraxis and Europroxima overestimated toxin concentration, especially 412 
those with ≤0.05 mg STX eq/kg, but none of them above 0.38 mg STX eq/kg.  413 
Shellfish extracts whose PST toxin content were outside the constructed calibration curve were under 414 
or overestimated, 30% (HCl extraction) to 60% (MeOH extraction) and 91% of samples were outside 415 
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the calibration curve for the Abraxis and Europroxima tests, respectively. This could be overcome by 416 
performing extra dilutions to make them fit the standard curve; however, re-testing those samples 417 
falling outside the calibration curve doubles the cost and time of analysis. Abraxis does recommend a 418 
further dilution of 1:10 in highly contaminated samples, however this dilution is not sufficient to 419 
obtain a satisfactory quantification since some samples contained up to 31.75 mg STX eq/kg. Extra 420 
dilutions of 1:100 or 1:500 were necessary for Abraxis and Europroxima, respectively, which 421 
improved toxin quantification significantly, although some samples were still underestimated: 2 with 422 
Abraxis and 1 with Europroxima, reporting compliant toxin levels when in fact they contained >0.80 423 
mg STX eq/kg (as per LC-FLD). Costa et al. (2009) also performed extra dilutions to bring mussel 424 
and clam extracts within the working range of Abraxis. These authors obtained a correlation (r2=0.87) 425 
comparable to the one we observed (r2=0.82-0.91) and similarly reported underestimation in some 426 
samples above the regulatory action limit, thus recommending that this ELISA kit was not suitable for 427 
samples containing multiple PST analogues. DeGrasse et al. (2014a) compared Scotia with a modified 428 
Abraxis kit on surf clams, and reported that Abraxis accurately detected high PST in shellfish 429 
contaminated with mostly STX (82%). The difference was claimed due to Scotia having been 430 
calibrated against a mixture of PST toxins, whereas Abraxis uses STX for the standard curve. Abraxis 431 
proved to be unreliable for samples contaminated with analogues other than STX, especially 432 
GTX1&4 for which reactivity is <0.2%. 433 
Although Neogen standard protocol claims to return positive results for samples ≥0.8 mg STX eq/kg, 434 
Jawaid et al. (2015) reported a cut off of 0.68 mg STX eq/kg. In our work we observed a cut off of 0.4 435 
mg STX eq/kg, and hence increased the dilution in the extraction step to increase the cut off to 0.5-0.6 436 
mg STX eq/kg as suggested by Tasmanian shellfish growers. Jawaid et al. (2015) observed 38% false 437 
positives (samples with 0.265-0.408 mg STX eq/kg), whereas we observed 13% false positives in our 438 
samples (samples with 0.03 to <0.35 mg STX eq/kg). While Jawaid et al. (2015) did not observe false 439 
negatives, we found 5% false negatives in our Tasmanian studies (two samples containing 0.82 and 440 
0.92 mg STX eq/kg). This difference might be due to the fact that (i) we included more samples in the 441 
range 0.5-1.3 mg STX eq/kg, (ii) our samples contained a higher proportion of GTX1&4 (low cross-442 
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reactivity by the Neogen and all kits), or (iii) because of the greater dilution we performed. It should 443 
be noted that the screen by LC-FLD for one of the false negative samples (with 0.82 mg STX eq/kg, 444 
confirmation result) was less than the regulatory limit (0.59 mg STX eq/kg screen result), and 445 
homogeneity could play a role in the differentiation of this sample; however, considering the screen 446 
result of that particular sample, a positive result was expected. The novel introduction in our work of 447 
cysteine treatment effectively overcame the false negatives due to conversion of GTX1&4 to NEO, 448 
and GTX2&3 to STX, as it has been shown by this and other thiol compounds (Asakawa et al., 1987; 449 
Sakamoto et al., 2000). This conversion step was more convenient with the Neogen kit since it 450 
possess the highest reactivity for NEO (129%, Table 1), and while it could generate false positives, 451 
this would not be as serious as for the Scotia kit (Table 3). Costa et al. (2009) recommended extra 452 
sample dilutions for Scotia to avoid false positives, but Turner et al. (2015) concluded that attempting 453 
to fine-tune the sensitivity of Scotia through extra dilutions is potentially unsafe. In our work we 454 
observed that by adjusting the dilution of the Neogen protocol and introducing a cysteine conversion 455 
step (increasing test time by 30 min), it eliminated false negatives. Furthermore, the Neogen kit also 456 
proved to perform well for contaminated samples from the 2012 Tasmanian bloom, which were 457 
dominated by GTX2&3 (samples used for early work, data not shown). 458 
Turner et al. (2015) reported that Scotia returned negative results in samples up to 0.35 mg STX 459 
eq/kg. In their work the use of an extra hydrolysis step increased variability since samples with 0.10-460 
0.70 mg STX eq/kg delivered positive results (improvement in performance), even though some (i.e. 461 
0.10-0.23 mg STX eq/kg) were reported as negative. These authors observed many false positives 462 
without the extra step, 50% in samples with <0.1 mg STX eq/kg (including three samples with 0.01-463 
0.08 mg STX eq/kg), and >95% in samples between 0.1 and 0.2 mg STX eq/kg. In the present 464 
Tasmanian study we observed 53.8% false positives in samples with <0.1 mg STX eq/kg, and 75% in 465 
samples between 0.1 and 0.2 mg STX eq/kg. Costa et al. (2009), DeGrasse et al. (2014a), and Wong 466 
et al. (2010) all previously reported a high percentage of false positives using Scotia (>58%). The kits 467 
these authors used were claimed to have a detection limit of 0.4 mg STX eq/kg (Jellett et al., 2002), 468 
but DeGrasse et al. (2014a) found that the practical detection limit was 0.1 to 0.2 mg STX eq/kg. The 469 
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introduction of the Scotia Skannex system improved problems with subjective visual comparison of 470 
band intensities (Turner et al., 2015). We did not observe any false negatives with the Scotia kits, but 471 
numerical values returned by the Scotia scanner and the toxin concentration determined by LC-FLD 472 
were not well correlated (r2=0.45) which might be due to the higher concentration of GTX1&4 in our 473 
samples. The correlation could have been improved by using the extra hydrolysis step, but was not 474 
necessary for our samples since we did not obtain any false negatives. The introduction of a 475 
conversion step for the Neogen kit presented in this study, by incubating GTX1&4 standards and 476 
shellfish samples with cysteine, successfully eliminated false negatives. More work is being 477 
performed to fine-tune this extra step. 478 
The Neogen kit was elected as the most suitable tool for our purposes since it offers advantages over 479 
other kits: (i) it is more user friendly and laboratory experience is not required, (ii) it returns faster 480 
results (~20-35 min), and (iii) is more practical for field use; (iv) it returned a lower number of false 481 
positives, and although 5% of false negatives were obtained, the introduction of a conversion step to 482 
increase the sensitivity of GTX1&4 successfully eliminated these false negatives. An international 483 
validation including Neogen standard protocol and the modification proposed in this study (i.e. altered 484 
dilution to change cut off and introduction of cysteine conversion step) is in process to facilitate 485 
approval of the Neogen kit for regulatory purposes as a screening tool. Significant savings in 486 
analytical costs will result when Neogen negative screen samples will no longer need to be tested 487 
using the more expensive and time consuming LC-FLD method. 488 
Associated content 489 
Supplementary material 490 
Additional information includes: detailed PST toxin profile of the 69 shellfish samples used in this 491 
study; figures and results of standard curves performed with the Neogen test kit using PST standards 492 
under supplier’s standard conditions and our altered protocol (i.e. dilution during extraction), this also 493 
includes a conversion step for GTX1&4. A figure showing the performance of the Neogen kit on the 494 
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69 shellfish extracts is also shown, as well as a table with the numerical values returned by the Scotia 495 
Skannex and the Neogen AccuScan Pro reader for the 69 shellfish tests. 496 
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